Ocugen, Inc. (NASDAQ: OCGN) is now covered by analysts at Maxim Group. They set a "buy" rating and a $4.00 price target on the stock.
Ocugen, Inc. (OCGN)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular EdemaGlobeNewswire
- Ocugen, Inc. (NASDAQ: OCGN) had its price target raised by analysts at Chardan Capital from $6.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs [Yahoo! Finance]Yahoo! Finance
- Ocugen (OCGN) Q4 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
OCGN
Earnings
- 3/5/25 - In-Line
OCGN
Sec Filings
- 3/5/25 - Form S-8
- 3/5/25 - Form 10-K
- 3/5/25 - Form 8-K
- OCGN's page on the SEC website